Magali is responsible for the regulatory affairs strategy at the Pharmabiotic Research Institute (PRI), a European association specialising in science and regulatory affairs within the world of microbiotic medicinal products (MMPs, pharmabiotics). She is responsible for the coordination and support of the member companies in their scientific advice requests at the EMA as well as the updating of the PRI internal guideline and collaborative knowledge.
She also represent the PRI in any discussions or task groups working on the evolution of the regulatory framework for MMPs.
Her major objectives at the moment is to develop awareness on the regulatory challenge regarding LBPs, develop and provide trainings for the PRI regulatory members on the collaborative regulatory knowledge acquired by the PRI, and to develop and coordinate the regulatory strategy of the association. She works closely with the Business Development Manager and together they report to and execute the PRI Board of Directors decisions.